KR20140117433A - 재조합 독소를 포함하는, 클로스트리디움 디피실레에 대한 백신 - Google Patents

재조합 독소를 포함하는, 클로스트리디움 디피실레에 대한 백신 Download PDF

Info

Publication number
KR20140117433A
KR20140117433A KR1020147020672A KR20147020672A KR20140117433A KR 20140117433 A KR20140117433 A KR 20140117433A KR 1020147020672 A KR1020147020672 A KR 1020147020672A KR 20147020672 A KR20147020672 A KR 20147020672A KR 20140117433 A KR20140117433 A KR 20140117433A
Authority
KR
South Korea
Prior art keywords
asn
ile
leu
lys
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147020672A
Other languages
English (en)
Korean (ko)
Inventor
존 헨리 하인리히스
장-뤽 보드머
수잔 린 세코어
아론 루디 괴르케
이베트 카로-아귈라
마리-피에르 젠틸레
멜라니 에스. 호르톤
매튜 라이언 미자이에브스키
줄리 엠. 스키너
파울루스 야코부스 안토니우스 손더마이예르
샤이암순다르 수브라마니안
카린 후버디나 안토니아 판 데르 하예덴-리에프켄스
수 왕
진푸 셰
레이첼 플로라 소코노스틀레
줄리 케이. 조르만
Original Assignee
머크 샤프 앤드 돔 코포레이션
인터벳 인터내셔널 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 머크 샤프 앤드 돔 코포레이션, 인터벳 인터내셔널 비.브이. filed Critical 머크 샤프 앤드 돔 코포레이션
Publication of KR20140117433A publication Critical patent/KR20140117433A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020147020672A 2012-01-27 2013-01-25 재조합 독소를 포함하는, 클로스트리디움 디피실레에 대한 백신 Withdrawn KR20140117433A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261591631P 2012-01-27 2012-01-27
US61/591,631 2012-01-27
US201261596419P 2012-02-08 2012-02-08
US61/596,419 2012-02-08
US201261703754P 2012-09-20 2012-09-20
US61/703,754 2012-09-20
PCT/US2013/023189 WO2013112867A1 (en) 2012-01-27 2013-01-25 Vaccines against clostridium difficile comprising recombinant toxins

Publications (1)

Publication Number Publication Date
KR20140117433A true KR20140117433A (ko) 2014-10-07

Family

ID=48873956

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147020672A Withdrawn KR20140117433A (ko) 2012-01-27 2013-01-25 재조합 독소를 포함하는, 클로스트리디움 디피실레에 대한 백신

Country Status (14)

Country Link
US (1) US9388394B2 (enExample)
EP (1) EP2807186A4 (enExample)
JP (2) JP2015506948A (enExample)
KR (1) KR20140117433A (enExample)
CN (1) CN104039816B (enExample)
AR (1) AR089797A1 (enExample)
AU (1) AU2013211973B2 (enExample)
BR (1) BR112014018432A8 (enExample)
CA (1) CA2856443A1 (enExample)
IN (1) IN2014CN04187A (enExample)
MX (1) MX351074B (enExample)
RU (1) RU2014134365A (enExample)
TW (1) TW201335178A (enExample)
WO (1) WO2013112867A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
AU2012349753A1 (en) * 2011-12-08 2014-06-19 Novartis Ag Clostridium difficile toxin-based vaccine
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
CN105451762A (zh) * 2013-04-22 2016-03-30 俄克拉荷马州大学评议会 艰难梭菌疫苗及使用方法
WO2014197651A1 (en) * 2013-06-05 2014-12-11 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
BE1022949B1 (fr) 2014-06-25 2016-10-21 Glaxosmithkline Biologicals S.A. Composition immunogene
JP2017212882A (ja) * 2014-10-10 2017-12-07 学校法人 名城大学 アセチルエステラーゼ及びその利用
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
BR112017024443A2 (pt) 2015-05-15 2018-10-23 Sanofi Pasteur Inc métodos para imunização contra clostridium difficile
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
MX395130B (es) 2016-03-02 2025-03-24 Merz Pharma Gmbh & Co Kgaa Composicion que comprende toxina botulinica
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
BR112019012203A2 (pt) * 2016-12-14 2019-11-12 Beijing Genomics Inst At Shenzhen marcadores genéticos humanos associados à resposta para tratamentos que têm como alvo a toxina b de clostridium difficile
US10668140B2 (en) 2017-02-24 2020-06-02 University Of South Floirida Non-toxigenic Clostridium difficile spores for use in oral vaccination
CN110691609B (zh) * 2017-03-15 2024-04-19 诺瓦瓦克斯股份有限公司 用于诱导针对艰难梭菌的免疫应答的方法和组合物
US10555992B2 (en) 2017-05-31 2020-02-11 University Of South Florida Immunogenic proteins against clostridium difficile
MX388528B (es) 2017-06-09 2025-03-20 Hipra Scient S L U Vacuna que comprende toxoides de clostridium.
EP3642222A1 (en) 2017-06-20 2020-04-29 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
US11155802B2 (en) 2017-07-06 2021-10-26 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum neurotoxins with increased duration of effect
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
WO2020078420A1 (en) * 2018-10-17 2020-04-23 Eternity Biomedical Laboratories, Inc. Immunogenic preparations and methods against clostridium difficile infection
CN110041437B (zh) * 2019-04-29 2020-12-25 中国兽医药品监察所 一种无毒性破伤风毒素和诺维梭菌α毒素重组融合蛋白
CN110607314B (zh) * 2019-10-31 2022-09-23 四川农业大学 一种TcdB RBD基因、重组RBD蛋白和应用
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
CN112442472B (zh) * 2020-11-30 2023-05-26 四川大学华西医院 抗艰难梭菌的重组乳酸乳球菌、活载体疫苗及其制备方法
CN118613492A (zh) * 2022-01-30 2024-09-06 西湖大学 Tfpi结合多肽及其用途
JP7814993B2 (ja) * 2022-03-15 2026-02-17 株式会社荏原製作所 研磨方法および研磨装置
WO2025029561A2 (en) * 2023-07-28 2025-02-06 University Of South Florida Vaccine containing rbd2 of cdtb component from binary toxin cdt of clostridioides difficile

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
AU746859B2 (en) 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
EP2305303A3 (en) 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
AU2003299527A1 (en) 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
KR101138131B1 (ko) 2003-12-08 2012-04-23 이데라 파마슈티칼즈, 인코포레이티드 작은 올리고뉴클레오티드-기초 화합물에 의한 면역자극특성의 조절
ES2366626T3 (es) 2004-02-06 2011-10-24 University Of Massachusetts Anticuerpos contra toxinas de clostridium difficile y usos de los mismos.
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
WO2007126816A2 (en) * 2006-03-30 2007-11-08 Embrex, Inc. Methods and compositions for vaccination of poultry
US9110081B2 (en) 2009-02-11 2015-08-18 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US8709428B2 (en) * 2009-02-20 2014-04-29 Health Protection Agency Antibodies to Clostridium difficile toxins
EP2470664A4 (en) * 2009-08-27 2013-01-16 Synaptic Res Llc NEW PROTEIN RELEASE SYSTEM FOR GENERATING INDUCED PLURIPOTENTAL STEM CELLS OR TISSUE-SPECIFIC CELLS
WO2011060431A2 (en) 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease
JP2013512916A (ja) 2009-12-02 2013-04-18 タフツ ユニバーシティー 免疫原としてのClostridiumdifficileの無毒の組換えホロトキシン
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
KR101907434B1 (ko) 2010-09-03 2018-10-12 발네바 오스트리아 게엠베하 C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도
US8431361B2 (en) * 2010-09-17 2013-04-30 Board Of Regents Of The University Of Oklahoma Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B
AR086199A1 (es) * 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos

Also Published As

Publication number Publication date
AU2013211973B2 (en) 2017-10-12
JP2017141226A (ja) 2017-08-17
US9388394B2 (en) 2016-07-12
US20150044250A1 (en) 2015-02-12
TW201335178A (zh) 2013-09-01
EP2807186A1 (en) 2014-12-03
WO2013112867A1 (en) 2013-08-01
CN104039816A (zh) 2014-09-10
CA2856443A1 (en) 2013-08-01
AU2013211973A1 (en) 2014-06-12
CN104039816B (zh) 2018-02-09
EP2807186A4 (en) 2016-01-27
AR089797A1 (es) 2014-09-17
RU2014134365A (ru) 2016-03-20
MX2014009106A (es) 2014-11-10
BR112014018432A2 (enExample) 2017-06-20
JP2015506948A (ja) 2015-03-05
MX351074B (es) 2017-09-28
BR112014018432A8 (pt) 2017-07-11
IN2014CN04187A (enExample) 2015-07-17

Similar Documents

Publication Publication Date Title
AU2019203159B2 (en) Compositions and methods relating to a mutant clostridium difficile toxin
AU2020230248B2 (en) Compositions relating to a mutant Clostridium difficile toxin and methods thereof
AU2013211973B2 (en) Vaccines against clostridium difficile comprising recombinant toxins
AU2017371484B2 (en) Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof
RU2725726C2 (ru) Бактериофаги, фаговые пептиды и способы их применения
KR101907434B1 (ko) C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도
KR20140101835A (ko) 클로스트리듐 디피실레 톡신-기반 백신
AU2018343217B2 (en) Compositions and methods for eliciting an immune response against Clostridium difficile
KR20150056540A (ko) 백신으로서의 클로스트리듐 디피실 폴리펩티드
KR102224897B1 (ko) 신규한 폴리펩타이드 및 이를 포함하는 그람음성균에 대한 항생제
CN110691609B (zh) 用于诱导针对艰难梭菌的免疫应答的方法和组合物
DK2576604T3 (en) DIFFOCINES AND METHODS OF USING THEREOF
AU2021240230B2 (en) Vaccines and vaccine components for inhibition of microbial cells
RU2773880C1 (ru) Композиции, относящиеся к мутантному токсину CLOSTRIDIUM DIFFICILE, и способы их применения
KR20260018598A (ko) 신규한 박테리오파지 pbec124 및 엔지니어링 기술
KR20160146217A (ko) 비브리오 패혈증균의 시스테인 단백질 분해효소 도메인 유래 재조합 단백질 및 이의 용도

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140723

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid